2269:HKG
WuXi Biologics (Cayman) Inc
48,20 HKD
arrow_downward
-0,90%(-0,44) 1D
16 ოქტ, 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2269...
Open
49,98 HKD
High
50,85 HKD
Low
45,82 HKD
Mkt. cap
198,43 მლრ.
Avg. vol.
30,42 მლნ.
Volume
55,18 მლნ.
P/E ratio
34,48
52-wk high
58,00 HKD
52-wk low
28,48 HKD
EPS
1,40 HKD
Shares outstanding
1,23 მლრდ.
No. of employees
15 ათ.
Open
49,98 HKD
High
50,85 HKD
Low
45,82 HKD
Mkt. cap
198,43 მლრ.
Avg. vol.
30,42 მლნ.
Volume
55,18 მლნ.
P/E ratio
34,48
52-wk high
58,00 HKD
52-wk low
28,48 HKD
EPS
1,40 HKD
Shares outstanding
1,23 მლრდ.
No. of employees
15 ათ.
News stories
From web sources and news partners
AskTraders.com
·
42 წუთის წინ
S&P 500 Can Absorb Fed Hikes, Says UBS CIO After Hot US Inflation
Foreign Policy Journal
·
1 საათის წინ
Rigetti Computing (NASDAQ: RGTI) Stock Drops 21% In A Month As Quantum Sector Faces Commercialization Pressure
Traders Union
·
1 საათის წინ
Peter Tuchman: Nasdaq posts worst week since April 2025 tariff selloff as S&P 500 loses $1.3 trillion
Yahoo Finance
·
10 საათის წინ
Michael Burry Warns of a Stock Market ‘Supervolcano’
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About WuXi Biologics (Cayman) Inc